Literature DB >> 8188470

Topical application of a cyclic GMP analog lowers IOP in normal and ocular hypertensive rabbits.

P J Stein1, J W Clack.   

Abstract

PURPOSE: To determine whether a new cyclic GMP analog, 2'-O-(4-benzoyl)benzoylguanosine 3',5' cyclic monophosphate (BB-cGMP), significantly reduces intraocular pressure in either normotensive or hypertensive eyes of rabbits.
METHODS: Intraocular pressure of normal adult rabbits and/or rabbits with alpha-chymotrypsin-induced ocular hypertension was measured after topical application of BB-cGMP for up to 72 hours after treatment.
RESULTS: Data indicate that topical application of solutions containing BB-cGMP can significantly reduce intraocular pressure in normotensive eyes and, to a greater extent, hypertensive eyes for periods up to 12 hours for a single dose.
CONCLUSIONS: BB-cGMP holds interest both as a clinical agent in the management of intraocular pressure and for in vitro biochemical studies on the regulation of intraocular pressure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188470

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  3 in total

1.  MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure.

Authors:  Padmanabhan P Pattabiraman; Paula E Pecen; Ponugoti Vasantha Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-05       Impact factor: 4.799

2.  Characterization of intraocular pressure responses of the Tibetan monkey (Macaca thibetana).

Authors:  Guo Liu; Tao Zeng; Wenhan Yu; Naihong Yan; Hongxing Wang; Su-ping Cai; Iok-Hou Pang; Xuyang Liu
Journal:  Mol Vis       Date:  2011-05-27       Impact factor: 2.367

3.  Hybrid formulations of liposomes and bioadhesive polymers improve the hypotensive effect of the melatonin analogue 5-MCA-NAT in rabbit eyes.

Authors:  Daniela Quinteros; Marta Vicario-de-la-Torre; Vanessa Andrés-Guerrero; Santiago Palma; Daniel Allemandi; Rocío Herrero-Vanrell; Irene T Molina-Martínez
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.